Q-omics provides the consensus-scored KCTD17 profile across patient tissues and cancer cell-line models. KCTD17 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KCTD17 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, KCTD17 protein abundance shows 27,019 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where KCTD17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCTD17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCTD17 survival associations across molecular data types. KCTD17 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCTD17 RNA expression–survival associations across cancer types. High KCTD17 expression shows unfavorable associations in KIRC, UVM, MESO, ACC and LIHC, but favorable associations in SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KCTD17 RNA expression.
This table summarizes KCTD17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for KCTD17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCTD17 shows lower tumor expression in KICH and higher tumor expression in HNSC, KIRC, LIHC, THCA and BRCA. The HNSC box plot shows higher KCTD17 RNA expression in tumor versus normal tissue (log2 FC = +1.098, t-test p < 0.001).
This table shows molecular features associated with KCTD17 in patient tissues and cancer cell lines. In patient samples, KCTD17 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, KCTD17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
